Robert Little has over 30 years commercial experience in the Pharmaceutical, Biotechnology and Device industries ,with many successes in Country Management, Global product Launches, and Business Development and Licensing. From 2006-2010, Mr. Little was VP and chief commericial officer at Halozyme, where he implemented a high performing commercial operations function at Halozyme including Business Development, Marketing, New Product Planning and Alliance Management, and helped to drove market cap from $100M to over $600M in four years. From 2003 -2006, Mr. Little was SVP at Neurocrine Biosciences, where he implemented a 200 strong commercial organization (Sales, Marketing, and New Product Planning) to initially co-promote Zoloft™ with Pfizer then eventually launch Indiplon for sleep disorders. Piror to 2003, Mr. Little was group vice president of global prescription business at Pharmacia after spending nearly 20 years at Pharmacia and Pharmacia & Upjohn. Mr. Little has had business experience working in 4 different countries, including many years working here in the US , and has deep experience in many therapeutic areas, particularly in Oncology, Endocrinology, Neuroscience, and Opthalmology. His additional successes include creating a global reimbursement and health outcomes function for a major Drug Company, as well as building ground up commercial organizations for three fledgling biotech companies. He has led successful licensing activities and over a 10 year period he created Licensing Agreements with an aggregate value of over 1 Billion dollars ( up front payments and milestones, excluding royalties).  

 Robert Little has over 30 years commercial experience in the Pharmaceutical, Biotechnology and Device industries ,with many successes in Country Management, Global product Launches, and Business Development and Licensing. From 2006-2010, Mr. Little was VP and chief commericial officer at Halozyme, where he implemented a high performing commercial operations function at Halozyme including Business Development, Marketing, New Product Planning and Alliance Management, and helped to drove market cap from $100M to over $600M in four years. From 2003 -2006, Mr. Little was SVP at Neurocrine Biosciences, where he implemented a 200 strong commercial organization (Sales, Marketing, and New Product Planning) to initially co-promote Zoloft™ with Pfizer then eventually launch Indiplon for sleep disorders. Piror to 2003, Mr. Little was group vice president of global prescription business at Pharmacia after spending nearly 20 years at Pharmacia and Pharmacia & Upjohn. Mr. Little has had business experience working in 4 different countries, including many years working here in the US , and has deep experience in many therapeutic areas, particularly in Oncology, Endocrinology, Neuroscience, and Opthalmology. His additional successes include creating a global reimbursement and health outcomes function for a major Drug Company, as well as building ground up commercial organizations for three fledgling biotech companies. He has led successful licensing activities and over a 10 year period he created Licensing Agreements with an aggregate value of over 1 Billion dollars ( up front payments and milestones, excluding royalties).